BIOGEN INC. Proceeds from Notes Payable
BIOGEN INC. (BIIB) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2018-02-01
- BIOGEN INC. proceeds from notes payable for the quarter ending 2016-12-31 was $0.00.
- BIOGEN INC. proceeds from notes payable for the quarter ending 2015-12-31 was -$400.00K.
- BIOGEN INC. proceeds from notes payable for the quarter ending 2014-12-31 was $0.00.
- BIOGEN INC. proceeds from notes payable for fiscal 2017 was $0.00.
- BIOGEN INC. proceeds from notes payable for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- BIOGEN INC. proceeds from notes payable for fiscal 2015 was $5.93B.
- BIOGEN INC. proceeds from notes payable for fiscal 2014 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 9 month as first filed | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-01 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $0.00 10-K · filed 2018-02-01 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-10-26 | |||
| 2015-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $5.93B 10-K · filed 2018-02-01 | ||
| 2015-09-30 | $5.93B 10-Q · filed 2016-10-26 | $5.93B 10-Q · filed 2015-10-21 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $0.00 10-K · filed 2017-02-02 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-10-21 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |